Cabotegravir Sodium

Specifications

1051375-13-3CAS Number

857-514-0EC Number

sodium (3R,6S)-12-[(2,4-difluorophenyl)methylcarbamoyl]-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-dien-10-olateIUPAC Name

C19H16F2N3NaO5Chemical Formula

427.3 g/molMolecular Weight

Cabotegravir sodium; 1051375-13-3; Vocabria; GSK1265744B; GSK-1265744B; S-265744B; S 265744B; 3L12PT535M; CHEBI:172948; Oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide, N-((2,4-difluorophenyl)methyl)-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, sodium salt (1:1), (3S,11aR)-; Sodium (3S,11aR)-8-(((2,4-difluorophenyl)methyl)carbamoyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo(3,2-a)pyrido(1,2-d)pyrazin-6-olate; Sodium (3S,11aR)-8-{[(2,4-difluorophenyl)methyl]carbamoyl}-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazin-6-olate; RefChem:54589; 857-514-0; Cabotegravir sodium [USAN]; Sodium (3S,11aR)-8-((2,4-difluorobenzyl)carbamoyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazin-6-olate; Cabotegravir (sodium); Vocabria (TN); sodium;(3R,6S)-12-[(2,4-difluorophenyl)methylcarbamoyl]-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-dien-10-olate; UNII-3L12PT535M; Cabotegravir Sodium?; C19H16F2N3NaO5; orb1908995; CHEMBL3137330; SCHEMBL29393452; Cabotegravir sodium (JAN/USAN); CABOTEGRAVIR SODIUM [JAN]; CABOTEGRAVIR SODIUM [WHO-DD]; EBC-97034; GSK 1265744B; HY-15592A; CABOTEGRAVIR SODIUM [ORANGE BOOK]; AC-30853; DA-51525; CS-0007799; D10549; F11513; T62328; Q27257476; (3S,11aR)-N-(2,4-Difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, sodium salt; sodium (3S,11aR)-8-[(2,4-difluorobenzyl)carbamoyl]-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazin-6-olate; Sodium(3S,11aR)-8-((2,4-difluorobenzyl)carbamoyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazin-6-olate; Cabotegravir Sodium MicronizedSynonyms